Cargando…
1556. Infectious Disease Complications with Use of Checkpoint Inhibitors in Solid Organ Malignancies
BACKGROUND: Immune checkpoint inhibitors (ICIs) are innovative cancer immunotherapies used for solid-organ and hematologic malignancies. ICIs are known for their immune-related adverse events (irAE) but there are limited reports on infectious complications of immunosuppression for these complication...
Autores principales: | Komoda, Kellie, Ross, Justine Abella, Margolin, Kim, Pal, Sumanta, Dickter, Jana, Ito, James, Salgia, Ravi, Dadwal, Sanjeet |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6252963/ http://dx.doi.org/10.1093/ofid/ofy210.1384 |
Ejemplares similares
-
Infectious complications of immune checkpoint inhibitors in solid organ malignancies
por: Ross, Justine Abella, et al.
Publicado: (2021) -
1760. Outcomes of Acyclovir-Resistant Herpes Simplex Virus Infections in Hematologic Malignancies and Hematopoietic Cell Transplant
por: Ross, Justine Abella, et al.
Publicado: (2019) -
2617. Antiviral usage for herpes simplex virus (HSV) detected in bronchoalveolar lavage fluid (BALF) by polymerase chain reaction (PCR) in hematologic malignancy (HM) and solid organ malignancy (SOM) patients with pulmonary infiltrates; impact of infectious disease consultation (IDC) on antiviral stewardship
por: Fu, Cynthia, et al.
Publicado: (2023) -
1267. Implementation and Outcomes of Beta-lactam Allergy Management Protocol at a Comprehensive Cancer Center
por: Khalak, Sohanabanu, et al.
Publicado: (2023) -
Identification of M. tuberculosis Rv3441c and M. smegmatis MSMEG_1556 and Essentiality of M. smegmatis MSMEG_1556
por: Li, Shuang, et al.
Publicado: (2012)